Phase

n/a (2,535)

phase 2 (1,400)

phase 3 (640)

phase 4 (451)

phase 1 (347)

phase 1/phase 2 (244)

phase 2/phase 3 (102)

early phase 1 (67)

Study Documents

Clinical Study Report (7)

Study Protocol (7)

Individual Participant Data Set (6)

Informed Consent Form (6)

Dataset Specification (5)

Statistical Analysis Plan (5)

Annotated Case Report Form (4)

CSR Synopsis (1)

Published article (1)

Funder Type

Other (7,062)

Industry (469)

NIH (73)

U.S. Fed (42)

Study Type

Interventional (5,786)

Observational (1,638)

Observational [Patient Registry] (220)

Expanded Access (2)

Preoperative Concurrent Chemoradiotherapy

Showing 1 - 25 of 7,646

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer Trial in Guangzhou (drug, radiation, procedure)

Recruiting

Squamous Cell Esophageal Carcinoma
+2 more

Sintilimab
+4 more

Guangzhou, Guangdong, China

Sun Yat-sen University Cancer Center

Nov 11, 2022

Rectal Cancer Trial in Chongqing (CIETAI-R)

Recruiting

Rectal Cancer

CIETAI-R

Chongqing, Chongqing, China

Daping Hospital, Third Military Medical University

Jul 21, 2023

Gastroesophageal Junction Adenocarcinoma Trial in Shijiazhuang (Oxaliplatin; Capecitabine, Oxaliplatin; Capecitabine; concurrent

Completed

Gastroesophageal Junction Adenocarcinoma

Oxaliplatin; Capecitabine
Oxaliplatin; Capecitabine; concurrent radiotherapy

Shijiazhuang, Hebei, China

Department of General Surgery

Feb 4, 2022

Lymph Node Metastasis, Cancer of Rectum and Anus, Oxaliplatin Trial in Beijing (Experimental: FOLFOXIRI and Lateral lymph node

Enrolling by invitation

Lymph Node Metastasis
+6 more

Experimental: FOLFOXIRI and Lateral lymph node dissection
Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection

Beijing, Beijing, China

Cancer Hospital, Chinese Academy of Medical Sciences, Peking Uni

Sep 15, 2023

Esophageal Cancer, Intensity-modulated Radiation Therapy, Concurrent Chemoradiotherapy Trial in Beijing (rhTPO)

Not yet recruiting

Esophageal Cancer
+3 more

rhTPO

Beijing, Beijing, China

Department of Radiation Oncology, Cancer Institute and Hospital,

Jul 12, 2023

Stomach Tumors, Esophagogastric Junction Disorder, Neoadjuvant Therapy Trial in Shanghai (drug, radiation, procedure)

Recruiting

Stomach Neoplasms
+7 more

Oxaliplatin
+4 more

Shanghai, China

Fudan University Shanghai Cancer Center

Dec 3, 2021

Lung Tumors Trial (Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy), Envafolimab combined

Not yet recruiting

Lung Neoplasms

Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)
Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)

(no location specified)

Jun 12, 2023

Cervical Cancer Trial (Adebrelimab)

Not yet recruiting

Cervical Cancer

Adebrelimab

(no location specified)

Nov 28, 2023

Esophageal Carcinoma Trial in Nanjing (Nimotuzumab, Tigio, Concurrent radiation therapy)

Enrolling by invitation

Esophageal Carcinoma

Nimotuzumab
+2 more

Nanjing, Jiangsu, China

The First Affiliated Hospital of Nanjing Medical University

Sep 19, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou, Zhongshan, Nanning (IMRT and concurrent cisplatin, gemcitabine and cisplatin

Not yet recruiting

Nasopharyngeal Carcinoma

IMRT and concurrent cisplatin
gemcitabine and cisplatin (Induction chemotherapy)

Guangzhou, Guangdong, China
+3 more

Jul 30, 2023

To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced

Not yet recruiting

To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer

Hydrochloride anlotinib
+2 more

(no location specified)

Mar 6, 2023

Locally Advanced NSCLC, Efficacy and Safety Trial in Guangzhou (Anlotinib, Chemotherapy, Radiotherapy)

Recruiting

Locally Advanced Non-small Cell Lung Cancer
Efficacy and Safety

Anlotinib
+3 more

Guangzhou, Guangdong, China

Sun yat-sen University Cancer Center

Jul 28, 2022

Envafolimab Combined With Endostar and Concurrent

Not yet recruiting

Cervical Cancer

cis-platinum
+3 more

(no location specified)

May 19, 2023

Plasma MRD and cfDNA HPV and Efficacy and Prognosis of Locally

Recruiting

Locally Advanced Cervical Cancer

Concurrent chemoradiotherapy

Guiyang, Guizhou, China

Yong Li

Jul 14, 2023

Esophageal Squamous Cell Carcinoma Trial in Nanjing (Carrelizumab, Paclitaxel injection, Cisplatin)

Enrolling by invitation

Esophageal Squamous Cell Carcinoma

Carrelizumab
+3 more

Nanjing, China

The First Affiliated Hospital of Nanjing Medical University

Sep 19, 2023

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2),Immunotherapy

Not yet recruiting

Esophageal Squamous Cell Carcinoma

Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)